[ad_1]
The Schall Law Firma national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme, Inc. (“Cortexyme” or “the Company”) (NASDAQ: CRTX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Cortexyme issued a press release on October 26, 2021, “report[ing] top-line results from its Phase 2/3 GAIN Trial, a double-blind, placebo-controlled study evaluating the efficacy of atuzaginstat (COR388), an investigational orally administered small-molecule that targets gingipain proteases from the bacterium Porphyromonas gingivalis (P. gingivalis).” …
Full story available on Benzinga.com
[ad_2]
Source link
